Stent-based delivery of antisense oligodeoxynucleotides targeted to the PDGF A-chain decreases in-stent restenosis of the coronary artery

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 4, 2006, Pages 184-190

  Li, Yuxin ^a   Fukuda, Noboru ^b   Kunimoto, Satoshi ^a   Yokoyama, Shin Ichiro ^a   Hagikura, Kazuhiro ^a   Kawano, Taro ^a   Takayama, Tadateru ^a   Honye, Junko ^a   Kobayashi, Naohiko ^c   Mugishima, Hideo ^a   Saito, Satoshi ^a   Serie, Kazuo ^d  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d Gentier Biosystems Incorporation   (Japan)

Author keywords

Antisense oligonucleotides; Endothelialization; PDGF A chain; Restenosis

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PLATELET DERIVED GROWTH FACTOR A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ELUTING STENT; ENDOTHELIUM CELL; IMPLANTATION; IN-STENT RESTENOSIS; INTIMA; INTRAVASCULAR ULTRASOUND; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; SWINE; TREATMENT OUTCOME;

ANIMALS; CORONARY RESTENOSIS; CORONARY VESSELS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PLATELET-DERIVED GROWTH FACTOR; STENTS; SWINE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33750623904     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000246940.91191.1f     Document Type: Article

References (29)

1. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 1999;10:499-506.
2. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
3. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002;106:1949-1956.
4. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
5. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
6. Murakami M, Ichisaka T, Maeda M, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol. 2004;24:6710-6718.
7. Iakovou I, Sangiorgi GM, Stankovic G, et al. Effectiveness of sirolimus-eluting stent implantation for treatment of in-stent restenosis after brachytherapy failure. Am J Cardiol. 2004;94:351-354.
8. Werner GS, Emig U, Krack A, et al. Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis. Cath Cardiovasc Interv. 2004;63:259-264.
9. Hart CE, Forstrom JW, Kelly JD, et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988;240:1529-1531.
10. Johnsson A, Heldin CH, Westermark B, et al. Platelet-derived growth factor: identification of constituent polypeptide chains. Biochem Biophys Res Commun. 1982;104:66-74.
11. Nilsson J, Sjolund M, Palmberg L, et al. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci U S A. 1985;82:4418-4422.
12. Fukuda N, Kubo A, Watanabe Y, et al. Antisense oligodeoxynucleotide complementary to platelet-derived growth factor A-chain messenger RNA inhibits the arterial proliferation in spontaneously hypertensive rats without altering their blood pressures. J Hypertens. 1997;15:1123-1136.
13. Kishioka H, Fukuda N, Nakayama M, et al. Effect of methylene methylimino linkage of antisense oligonucleotide to the platelet-derived growth factor A-chain on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Eur J Pharmacol. 2000;392:129-132.
14. Kishioka H, Fukuda N, Wen-Yang H, et al. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2001;14:439-445.
15. Iyer RP, Phillips LR, Egan W, et al. The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagent. J Org Chem. 1990;55:4693-4699.
16. Boussif O, Lezoualc'h F, Zanta MA, et al. Aversatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92:7297-7301.
17. Jaschke B, Michaelis C, Milz S, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res. 2005;68:483-492.
18. Wong A, Chan C. Drug-eluting stents: the end of restenosis? Ann Acad Med Singapore. 2004;33:423-431.
19. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res. 2001;38:113-119.
20. Carmeliet P, Moons L, Dewerchin M, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci. 1997;811:191-206.
21. Majesky MW. Neointima formation after acute vascular injury. Role of counteradhesive extracellular matrix proteins. Tex Heart Inst J. 1994;21:78-85.
22. Shindo T, Manabe I, Fukushima Y, et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med. 2002;8:856-863.
23. Wellstein A, Zugmaier G, Califano JA 3rd, et al. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst. 1991;83:716-720.
24. Perez JR, Li Y, Stein CA, et al. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1994;91:5957-5961.
25. Kipshidze NN, Iversen P, Kim HS, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Cath Cardiovasc Interv. 2004;61:518-527.
26. Kutryk MJ, Foley DP, van den Brand M, et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol. 2002;39:281-287.
27. Hausleiter J, Kastrati A, Wessely R, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005;26:1475-1481.
28. Advani R, Peethambaram P, Lum BL, et al. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer. 2004;100:321-326.
29. Marshall J, Chen H, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004;15:1274-1283.